Hopp til innhold

Valgte elementer er lagt i handlekurven

Gå til handlekurv
Historisk arkiv: Dette innholdet er arkivert og blir ikke oppdatert.
Artikkel

Referanser til studier på MenBvac

Aaberge IS, et al. Immunogenicity and reactogenicity of meningococcal group B OMV vaccine and meningococcal group C conjugate vaccine given in combination. In Caugant DA and Wedege E (eds). Abstracts of the 13th International Pathogenic Neisseria Conference, Oslo 2002, Nordberg Aksidenstrykkeri AS, Oslo, p. 62.

Aaberge IS, Oster P, Helland OS, Kristoffersen A-C, Ypma E, Høiby EA, et al. Combined administration of a meningococcal serogroup B outer membrane vesicle (OMV) vaccine and a conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic. Clin Diagn Lab Immunol 2005;12:599-605. 

Aase A, Bjune G, Høiby EA, Rosenqvist E, Pedersen AK, Michaelsen TE. Comparison among opsonic activity, antimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect Immun 1995;63:3531-6. 

Aase A, Høiby EA and Michaelsen TE. Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine. Scand. J. Immunol. 1998;47:388-96. 

Aase A, Næss LM, Sandin RH, Herstad TK, Oftung F, Holst J, et al. Comparison of functional immune responses in humans after intranasal and intramuscular immunisations with outer membrane vesicle vaccines against group B meningococcal disease. Vaccine 2003;21:2042-51.

Aavitsland P, Bjune G, Aasen S, Halvorsen S. Adverse events following vaccine or placebo injection in an efficacy trial of an outer membrane vesicle vaccine against group B meningococcal disease in Norwegian secondary schools 1988-1991. NIPH Ann 1991;14:133-4.

Aavitsland P, Bjune G. Surveillance of adverse events in Phase IIIC of the Norwegian serogroup B meningococcal vaccine trial. Recent advances in chemotherapy. Proceedings of the 18th International Congress of Chemotherapy; 1993. p. 749-750.

Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-93.
Ada GL. The immunological principles of vaccination. Lancet 1990;335:523-6.

Al’Aldeen AA, Cartwright KA. Neisseria meningitidis: vaccines and vaccine candidates. J Infect 1996;33:153-7.
Berild D, Gedde-Dahl TW, Abrahamsen T. Meningococcal disease in the Norwegian armed forces 1967-1979. Some epidemiological aspects. NIPH Ann 1980;3:23-30.

Bjune G, Closs O, Grønnesby JK, Høiby EA, Nøkleby H. Design of clinical trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease. NIPH Ann 1991;14:81-93.

Bjune G, Grønnesby JK, Høiby EA, Closs O, Nøkleby H. Results of an efficacy trial with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann 1991;14:125-32.

Bjune G, Høiby EA, Djupesland P, Rosenqvist E, Wedege E, Aavitsland P, et al. Outer membrane vesicle vaccine against serogroup B meningococcal disease in Norway. Recent advances in chemotherapy. Proceedings of the 18th International Congress of Chemotherapy; 1993. p. 750-751.

Bjune G, Høiby EA, Grønnesby JK, Arnesen Ø, Fredriksen JH, Halstensen A et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6.

Bjæring-Hansen N. Utvikling av nye eksperimentelle yttermembranvesikkel-vaksiner mot gruppe B meningokokksykdom (in Norwegian). [Dissertation] Institute of Pharmacy, University of Oslo, 1997.

Bohr V, Hansen B, Kjersem H, Rasmussen N, Johnsen N, Kristensen HS, et al. Sequelae from bacterial meningitis and their relation to the clinical condition during acute illness, based on 667 questionnaire returns. Part II of a three part series. J Infect 1983;7:102-10.

Borrow R, Aaberge IS, Santos GF, Eudey TL, Oster P, Glennie A, et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup B, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol 2005;12:970-6.

Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection - serum bactericidal antibody activity. Vaccine 2005;23:2222–7.

Borrow R, Carlone GM. Serogroup B and C serum bactericidal assays. In: Pollard AJ, Maiden MCJ, eds. Methods in molecular medicine. 2001:289-304. 

Boslego J, Garcia J, Cruz C, Zollinger W, Brandt B, Ruiz S et al. Efficacy, safety and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquiqe, Chile. Vaccine 1995;13:821-9.

Bryn K, Sonesson A, Reistad R, Jantzen E. Chemical characterization of lipopolysaccharide of Neisseria meningitidis 44/76 (Abstract A-77), Stockholm:XIVth International Carbohydrate Symposium 1988.

Bøvre K, Frøholm LO, Gaustad P, Holten E, Høiby EA. Some agent characteristics and their coexistence related to occurrence and severity of systemic meningococcal disease Norway, winter 1981-1982. NIPH Ann 1983;6:75-84.

Bøvre K, Gedde-Dahl TW. Epidemiological patterns of meningococcal disease in Norway 1975-1979. NIPH Ann 1980;3:9-22.

Bøvre K, Holten E, Vik-Mo H, Brondbo A, Bratlid D, Bjark P, et al. Neisseria meningitidis infection in Northern Norway: An epidemic in 1974-1975 due mainly to group B organisms. J Infect Dis 1977;135:669-72.

Bøvre K. Meningococcal disease in Norway. Antonie van Leeuwenhoek 1986;52:208-11.

Cartwright K, Morris R, Rumke H, Fox A, Borrow R, Begg N, et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999;17:2612-19.

Caugant DA, Bøvre K, Gaustad P, Bryn K, Holten E, Høiby EA, Frøholm LO. Multilocus genotypes determined by enzyme electrophoresis of Neisseria meningitidis isolated from patients with systemic disease and from health carriers. J Gen Microbiol 1986;132: 641-52.

Caugant DA, Høiby EA, Magnus P, Scheel O, Hoel T, Wedege E, et al. Asymptomatic carriage of Neisseria meningitidis in a randomly sampled population. J Clin Microbiol 1994; 32:323-30.

Caugant DA, Høiby EA, Rosenqvist E, Frøholm LO, Selander RK. Transmission of Neisseria meningitidis among asymptomatic military recruits and antibody analysis. Epidem Inf 1992;109:241-53.

Caugant DA. Population genetics and molecular epidemiology of Neisseria meningitidis. APMIS 1998;106:505-25.

Centers for Disease Control and Prevention. Outbreaks of serogroup B meningococcal disease. MMWR 1998;47:833-7.

Cleary TG, Henle W, Pickering LG. Acute cerebellar ataxia associated with Epstein-Barr virus infection. JAMA 1980;243:148-9.

Costa W, Sacchi CT, Ramos S, Milagres L, Prigenzi LS. Meningococcal disease in São Paulo, Brazil. NIPH Ann 1991;14:215-8.

Czerkinsky CC, Nilsson L-Å, Nygren H, Ouchterlony Ö, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods 1983;65:109-21.

Davis J, Rowlatt RJ. Transient severe hypertension and polyradiculitus after chickenpox. Br Med J 1978;2:1608.

Delvig A, Wedege E, Caugant DA, Dalseg R, Kolberg J, Achtman M, Rosenqvist E. A linear B-cell epitope on the class 3 outer-membrane protein of Neisseria meningitidis recognized after vaccination with the Norwegian group B outer-membrane vesicle vaccine. Microbiology 1995;141:1593-1600. 

Djupesland G, Gedde-Dahl TW. Sequelae of meningococcal disease. Studied about six weeks after hospital admission. NIPH Ann 1983;6:85-90.

Djupesland P, Bjune G, Aanonsen NO, et al. Meningococcal disease in the Norwegian armed forces (in Norwegian with abstract in English). Nord Med 1990;105:179-81.

Djupesland PG, Bjune G, Høiby EA, Grønnesby JK, Mundal R. Serogroup B meningococcal disease in the Norwegian armed forces. What can we learn from an inconclusive vaccine protection trial? Eur J Public Health 1997;7:261-6.

Eng J, ed. Konsensusnotat om prøvetaking til mikrobiologisk diagnostik av sepsis og meningitt. Med særlig henblikk på sikring av etiologisk diagnose ved systematiske meningokokkinfeksjoner (in Norwegian). Oslo: NIPH Dept. of Bacteriology. 1988.

Feiring B, Fuglesang J, Oster P, Næss LM, Helland OS, Tilman S, et al. Persisting immune responses indicating long-term protection after booster dose with meningococcal group B outer membrane vesicle vaccine. Clin Vaccine Immunol. 2006;13:790-6.

Finne J, Leinonen M, Mäkelä PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2:355-57. 

Fischer M, Carlone GM, Holst J, Williams D, Stephens DS, Perkins BA. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease. Vaccine 1999;17:2377-83.

Fischer M. Use of an investigational serogroup B meningococcal outer membrane vesicle vaccine to immunize adult researchers with an occupational risk for meningococcal disease. IND#6308. December 15, 1997.

Fischer M. Use of an investigational serogroup B meningococcal outer membrane vesicle vaccine to immunize adult researchers with an occupational risk for meningococcal disease. IND#6308. November 20, 2000.

Fleiss JL. Statistical method for rates and proportions. 2nd ed. New York.Wiley & Sons, 1981:24-25.

Fleiss JL. Statistical method for rates and proportions. 2nd ed. New York. Wiley & Sons, 1981:74-75.

Frasch CE, van Alpen L, Holst J, Poolman JT, Rosenqvist E. Outer membrane protein vesicle vaccines for meningococcal disease. In A. J. Pollard and M.C.J. Maiden (ed.), Methods in Molecular Medicine, vol. 66. Meningococcal Vaccines. Human Press, Totowa NJ, USA. 2001, p. 81-107.

Frasch CE, Coetzee GJ, Wu L, Wang LY, Rosenqvist E. Immune responses of adults and children to group B Neisseria meningitidis outer membran protein vaccine. In: Robbins JB, Schneerson R, Klein D, Sadoff J, Hardegree MC,eds.: Bacterial vaccines. Praeger, New York 1987:262-72.

Frasch CE, Coetzee G, Zahradnik JM, Feldman HA, Koornhof HJ. Development and evaluation of group B serotype 2 vaccines: Report of a group B field trial. Med Trop 1983;43:177-180.

Frasch CE. Immunization against Neisseria meningitidis. In: Easmon CSF, Jeljaszewicz J, eds., Medical Microbiology, vol. 2, Immunization against bacterial diseases. Academic Press London and New York 1983:115-44.

Frasch CE. Meningococcal vaccines. In: Meningococcal disease, Cartwright K (ed.), John Wiley & Sons, New York 1995, p. 245-83.

Frasch CE. Status of a group B Neisseria meningitidis vaccine. Eur J Clin Microbiol 1985;4:533-6.

Frasch CE, Zahradnik JM, Wang LY, Mocca LF, Tsai C-M. Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine. J Infect Dis 1988;158:710-18.

Fredriksen JH, Rosenqvist E, Wedege E, Bryn K, Bjune G, Frøholm LO et al. Production, characterization and control of MenB-vaccine ”Folkehelsa”: An outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991;14:67-80.

Frøholm LO, Berdal BP, Bøvre K, Gaustad P, Halstensen AI, Harboe A, et al. Preliminary results from a clinical trial with a meningococcal vaccine containing serotype 2b and 15 antigens in complex with mixed A, C, Y and W135 polysaccharides. Antonie van Leevenhoek J Microbiol 1986;52:239-41.

Frøholm LO, Berdal BP, Bøvre K, Gaustad P, Harboe A, Holten E et al. Meningococcal group B vaccine trial in Norway 1981-1982. Preliminary report of results available November 1982. NIPH Ann 1983;6:133-38.

Frøholm LO, Caugant DA, Aasen S, Holten E. Recent meningococcal epidemiology in Norway: eight years of serotyping for strain characterisation. In: Achtman M, Marchal C, Morelli G, Seiler A. and Thiesen B, eds. Neisseriae 1990. Berlin: Walter de Gruyter, 1991:57-61.

Frøholm LO, Caugant DA, Holten E, Høiby EA, Rosenqvist E, Wedege E. Meningococcal strains isolated from teenage patients during the serogroup B vaccination trial in Norway: serotyping, serosubtyping, immunotyping and clonal analysis. NIPH Ann 1991;14:139-146.

Fuglesang JE, Helland O, Jenum PA, Aaberge IS, Harbak K, Ympa E, et al. Immunological response to the Norwegian meningococcal group B OMV vaccine in teen-agers with a condensed three-dose regimen. In: Caugant DA and Wedege E (eds). Abstract of the 13th International Pathogenic Neisseria Conference, Oslo, Norway, 2002, Nordberg Aksidenstrykkeri AS, Oslo. p.249. 

Fuglesang JE, Høiby EA, Holst J, Rosenqvist E, Nøkleby H. Increased and longer-lasting responses to the Norwegian meningococcal group B OMV vaccine in teenagers with a three-dose compared to a two-dose regimen. Poster presentation at the Eleventh International Pathogenic Neisseria Conference, Nice, France, November 1-6, 1998.

Gedde-Dahl TW, Høiby EA, Schillinger A, Lystad A, Bøvre K. An epidemiological, clinical and microbiological follow-up study og incident meningococcal disease cases in Norway, winter 1981-1982. Material and epidemiology in the MenOPP project. NIPH Ann 1983;6:155-68.

Granoff DM, Maslanka SE, Carlone GM, Plikaytis BD, Santos GF, Mokatrin A, et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998;5:479-485.

Griffiss JM. The special problems of carbohydrate vaccines. In: Nicholson BH, editor. Synthetic Vaccines. Blackwell, Oxford, 1994. Chapter 12.

Grimwood K, Anderson VA, Bond L, Catroppa C, Hore RL, Keir EH, et al. Adverse outcomes of bacterial meningitis in school-age survivors. Pediatrics 1995;95:646-56. 

Halstensen A, Lehmann AK, Guttormsen HK, Vollset SE, Bjune G, Næss A. Serum opsonins to serogroup B meningococci after disease and vaccination. NIPH Ann 1991;14:157-67.

Haneberg B, Dalseg R, Wedege E, Høiby EA, Haugen IL, Oftung F, et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun 1998;66: 1334-41.

Harthug S, Rosenqvist E, Høiby EA, Gedde-Dahl TW, Frøholm LO. Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigen. J Clin Microbiol 1986;24:947-53.

Helting TB, Guthöhrlein G, Blackkolb F, Ronneberger H. Serotype determinant protein of Neisseria meningitidis. Large scale preparation by direct detergent treatment of the bacterial cells. APMISC 1981;89:69-78.

Holst J, Feiring B, Fuglesang JE, Høiby EA, Nøkleby H, Aaberge IS, Rosenqvist E. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003,21:734-37.

Holten E. Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J Clin Microbiol 1979;9:186-8.

Holten E, Brunn JN, Hellum KB, Mæland JA. Diagnostic work with suspected cases of systemic meningococcal disease in the Norwegian serogroup vaccine protection trial. NIPH Ann 1991;14:103-5.

Hosking J, Rasanathan K, Mow FC, Jackson C, Martin D, O´Hallahan J, Oster P, Ypma E, Reid S, Aaberge I, Crengle S, Stewart J, Lennon D. Immunogenicity, Reactogenicity, and Safety of P1.7b,4 Strain-Specific Serogroup B Meningococcal Vaccine Given to Preteens. Clin Vaccine Immunol. 2007;14:1393-1399.

Høiby EA, Bjune G, Froholm LO, Eng J, Halstensen A, Rosenqvist E, et al. The Norwegian meningococcal serogroup B outer membrane vesicle vaccine protection trials: case tracing, meningococcal antigen detection and serological diagnosis. NIPH Ann 1991;14:107-21.

Høiby EA, Bruun JN, Andrew M, et al. Diagnose og behandling av systemisk meningokokksykdom (in Norwegian). Oslo: Norwegian Directorat of NIPH and Institute of Pharmacotherapy, University of Oslo, 1989.

Høiby EA, Moe PJ, Lystad A, Frøholm LO, Bøvre K. Phenoxymethyl-penicillin treatment of household contacts of meningococcal disease patients. Antonie van Leeuwenhoek 1986;52:255-7.

Høiby EA, Rosenqvist E, Bjune G, Closs O, Frøholm LO. Serological responses in Norwegian adult volunteers to a meningococcal 15:P1.16 outer membrane vesicle vaccine (Phase II studies). In: Achtman M, Kohl P, Marchal C, Morelli G, Seiler A. and Thiesen B, eds. Neisseriae 1990. Berlin: Walter de Gruyter, 1991:241-46.

Høiby EA, Rosenqvist E, Frøholm LO, Bjune G, Feiring B, Nøkleby H, et al. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann 1991;14:147-55.

Jackson C, Lennon DR, Sotutu VTK, et al.Phase II meningococcal B vesicle vaccine trial in New Zealand infants. Arch Dis Child 2009; 94: 745-751.

Jennings HJ, Lugowski C. Immunochemistry of group A, B and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol 1981; 127:1011-18.

Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariable methods. 2nd ed. PWS-KENT Publishing Co., Boston; 1988.

Kurstak E. Progress in enzyme immunoassays: production of reagents, experimental design, and interpretation. Bulletin W.H.O. 1985; 63:793-811.

Leach A, Twumasi PA, Kumah S, Banya WS, Jaffar S, Forrest BD, et al. Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine. J Inf Dis 1997;175:200-4.

Lennon D, Voss L, Sinclair J, Heffernan H. An outbreak of meningococcal disease in Auckland, New Zealand. Pediatr Infect Dis J. 1989;8:11-15.

van der Ley P, Steeghs L. Lessons from an LPS-deficient Neisseria meningitidis mutant. J Endotoxin Res 2003;9:124-28.

Lystad A, Aasen S. The epidemiology of meningococcal disease in Norway 1975-91. NIPH Ann 1991;14:57-66.

Løvoll Ø, Caugant DA, Frøholm LO. MSIS rapport: Meldingssystem for smittsomme sykdommer (weekly newsletter of the National Institute of Public Health, Oslo): Oslo 2001;29:15.

Løvoll Ø, Caugant DA, Frøholm LO. MSIS rapport: Meldingssystem for smittsomme sykdommer (weekly newsletter of the NIPH, Oslo): Oslo 2003;31:39.

MacDonald NNE, Halperin SA, Law BJ, Forrest B, Danzig LE, Granoff DM. Induction of immunologic memory by conjugated vs meningococcal C polysaccharide vaccine in toddlers. JAMA 1998;280:1685-89.

Marburg S, Jorn D, Tolman RL, Arison B, McCauley J, Kniskern PJ, et al. Bimolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein. J Am Chem Soc 1986;108:5282-87.

Martin D, McCallum L, Glennie A, Ruijne N, Blatchford P, O'Hallahan J, Oster P. Validation of the serum bactericidal assay for measurement of functional antibodies against group B meningococci associated with vaccine trials. Vaccine 2005;23:2218-21.

Martin DR, Walker SJ, Baker MG, Lennon DR. New Zealand epidemic of meningococcal disease identified by a strain with phenotype B4:P1.4 J. Infect Dis 1998;177: 497-500.

Michaelsen TE, Aase A. Antibody-induced opsonophagocytosis of serogroup B meningococci measured by flow cytometry. In: Methods in Molecular Medicine, vol. 66: Meningococcal Vaccines. Pollard AJ and Maiden MCJ (eds). Human Press, Totowa NJ, USA 2001, p. 331-7.

Milagres LG, Ramos SR, Sacchi CT, Melles CE, Vieira VS, Sato H, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: comparison with efficacy. Infect Imm 1994;62:4419-24.

Moe GR, Zuno-Mitchell P, Hammond SN, Granoff DM. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains. Infect Immun 2002;70:6021-31.

de Moraes JC, Camargo MC, Hidalgo NT, Barbosa HA, Sacchi CT, Landgraf IM, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-78.

Möller SA, Borrebäck CAK. A filter immuno-plaque assay for the detection of antibody-secreting cells in vitro. J Immunol Methods 1985;79:195-204.

MSIS. Reporting system for infectious diseases 2004;32:15.

Næss A, Halstensen A, Nyland H, Pedersen SHJ, Møller P, Borgmann R, et al. Sequelae one year after meningococcal disease. Acta Neurol Scand 1994;89:139-42.

Næss LM, Aarvak T, Aase A, Oftung F, Høiby EA, Sandin R, Michaelsen TE. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine. Vaccine 1999;17:754-64.

Næss LM, Oftung F, Aase A, Michaelsen TE, Pollard AJ. T-cell responses against meningococcal antigens. In Methods in Molecular Medicine, vol 66: Meningococcal vaccines, Pollard AJ and Maiden MCJ (eds.), Humana Press, NJ, USA 2001, p. 339-348.

Næss LM, Oftung F, Aase A, Wetzler LM, Sandin R, Michaelsen TE. Human T-cell response after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine. Infect Immun 1998;66:959-65.

Næss LM, Rosenqvist E, Høiby EA, Michaelsen TE. Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards. J Immunol Methods 1996;196:41-9.

Næss LM, Torill T, Kristoffersen A-C, Aaberge IS, Høiby EA, Rosenqvist E. Immunogenicity of a combination of two different outer membrane protein based meningococcal group B vaccines. In: Caugant DA and Wedege E, eds. Abstracts of the 13th International Pathogenic Neisseria Conference, Oslo 2002, Nordberg Aksidenstrykkeri AS, Oslo, p. 284.

Nøkleby H, Feiring B. The Norwegian meningococcal group B outer membrane vesicle vaccine: side effects in phase II trials. NIPH Ann. 1991;14:95-102.

Nøkleby H, Aavitsland P, O´Hallahan J, Feiring B, Tilman S, Oster P. Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitides serogroup B disease. Vaccine 2007;25: 3080-3084.

Orenstein WA, Bernier RH, Hinman AR. Assessing vaccine efficacy in the field. Epid Rev 1988;10:212-41.

Oster P, Lennon D, O´Hallahan J, Mulholland K, Reide S, Martin D. MeNZB™ a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain. Vaccine 2005;23:2191-6.

Oster P, O´Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007;25:3075-3079.

Pan American Health Organization, Washington, D.C. Immunogenicity and reactogenicity of two outer membrane protein-based anti-meningococcal serogroup B vaccines in Santiago, Chile. June 19-20, 1995.

Perkins BA, Jonsdottir K, Briem H, Griffiths E, Plikaytis BD, Høiby EA et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Inf Dis 1998;177:683-91.

Pfister H-W, Borasio GD, Dirnagl U, Bauer M, Einhäupl KM. Cerebrovascular complications of bacterial meningitis in adults. Neurology 1992;42:1497-1504.

Poolman JT, Jonsdottir K, Jones DM, Lind I, Frøholm LO, Zanen HC. Meningococcal serotypes and serogroup B disease in North-West Europe. Lancet 1986;2:555-8.

Poolman JT, Kriz-Kuzemenska P, Ashton F, Bibb W, Dankert J, Demina et al. Seroptypes and subtypes of Neisseria meningitidis: Results of an international study comparing sensitivities and specificities of monoclonal antibodies. Clin Diagnost Lab Immun 1995;2:69-72. 

Richmond P, Borrow R, Goldblatt D, Findlow J, Martin S, Morris R, et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after single dose in UK toddlers. J Inf Dis 2001;183:160-3.

Rosenqvist E, Bjune G, Feiring B, Eng J, Frøholm LO, Høiby EA, et al. Changes in carrier status of Neisseria meningitides in teenagers during a group B outer membrane vaccination trial in Norway. In: Conde-Glez CJ, Morse S, Rice P, Sparling F , Calderon E, eds. Pathobiology and Immunology of Neisseriacea. Proceedings of the VIII International Pathogenic Neisseria Conference. Cuernavaca, Morrelos, Mexico: Instituto Nacional de Saludo Pública 1994;895-901.

Rosenqvist E, Harthug S, Frøholm LO, Høiby EA, Bøvre K, Zollinger WD. Antibody responses to serogroup B meningococcal outer membrane antigens after vaccination and infection. J Clin Microbiol 1988;26:1543-8.

Rosenqvist E, Høiby EA, Bjune G, Aase A, Halstensen A, Lehmann AK, et al. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. In: Brown F, Haaheim LR, eds.: Modulation of the immune response to vaccine antigens. Dev Biol Stand, Basel Karger 1998;92:323-33.

Rosenqvist E, Høiby EA, Bjune G, Bryn K, Caugant DA, Closs O, et al. Meningococcal group B outer membrane vesicle vaccine trial among teenagers in Norway. Volume 1, 5.2. 1992. La Habana, Cuba. Adv. Modern Biotechnol.

Rosenqvist E, Høiby EA, Bjune G, Bryn K, Closs O, Feiring B, et al. Human antibody responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine: results from ELISA studies. NIPH Ann 1991;14:169-81.

Rosenqvist E, Høiby EA, Wedege E, Bryn K, Kolberg J, Klem A, et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995;63:4642-52.

Rosenqvist E, Høiby EA, Wedege E, Kusecek B, Achtman M. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J Inf Dis 1993;167:1065-73.

Rosenqvist E, Høiby EA. Relative bactericidal activity of IgG antibodies against outer membrane complexes from meningococci, as function of vaccine type, dose and time after vaccination, p. 265-269. In: Achtman M, Kohl P, Marchal C, Morelli G, Seiler A, Theisen B, eds. Neisseriae 1990. Proceedings of the 7th international pathogenic Neisseria conference; 1990 Sep 9-14; Berlin, Germany. New York: Walter de Gruyter; 1991.

Rosenqvist E, Musacchio A, Aase A, Høiby A, Namork E, Kolberg J, et al. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis. Inf Imm 1999;67:1267-76.

Rosenqvist E, Tangen T. Preclinical immunogenicity study in mice by OMV vaccines made from meningococcal strains from New Zealand and Norway. NIPH Internal report: Mouse experiment 16. June 27, 2006.

Rosenqvist E, Tangen T. Preclinical immunogenicity study in mice by OMV vaccines made from meningococcal strains from New Zealand and Norway. NIPH Internal report: Mouse experiment 17. June 27, 2006.

Rosenqvist E, Tjade T, Frøholm LO, Frasch CE. An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membran protein vaccine. NIPH Ann 1983;6:139-49.

Rosenqvist E, Wedege E, Høiby EA, Frøholm LO. Serogroup determination of Neisseria meningitidis by whole-cell ELISA, dot-blotting and agglutination. APMIS 1990;98:501-6.

Sandbu S, Feiring B, Oster P, Helland OS, Bakke HSW, Næss LM, Aase A, Aaberge IS, Kristoffersen AC, Rydland KM, Tilman S, Nøkleby H, Rosenqvist E. Immunogenicity and Safety of a Combination of Two Serogroup B Meningococcal Outer Membrane Vesicle Vaccines. Clin Vaccine Immunol 2007;14:1062-1069.

Sander J, Høst JH, Gedde-Dahl TW, Bay D, Borchgrevink HM, Frøholm LO, et al. Late sequelae after meningococcal disease as related to anamnestic and clinical factors recorded during the acute illness. NIPH Ann 1984;7:69-82.

Santos GF, Deck RR, Donnelly J, Blackwelder W, Granoff DM. Importance of complement source in measuring meningococcal bactericidal titers. Clin Diagn Lab Immunol 2001;8:616-23.

Sierra GVG, Campa HC, Garcia IL, Sotolongo PF, Izquierdo PL, Valcarcel NM, et al. Efficacy evaluateion of the Cuban vaccine VA-MENINGO-BC against disease caused by serogroup B Neisseria meningitidis. In: Achtman M, Marchal C, Morelli G, Seiler A, Thiesen B, eds. Neisseria 1990. Berlin, Federal Republic of Germany: Walter de Gruyter and Co., 1991:129-34.

Sierra GVG, Campa HC, Varcacel NM, Garcia IL, Izquierdio PL, Sotolongo PF, et al. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann 1991;14:195-210. 

Tangen T, Rosenqvist E. Preclinical immunogenicity studies in mice by OMV vaccines made from meningococcal strains from New Zealand and Norway. NIPH Internal report: Mouse experiment 15. June 27, 2006.

Tappero J, Gassibe P, Castillo L, Reeves M, Perkins B. Epidemic of clonal serogroup B meningococcal disease in Chile. In: Program and abstracts of the 34th interscience conference on antimicrobial agents and chemotherapy; October 4-7, 1994: Orlando, Fla. Abstract J13.

Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, et al. Serum bactericidal activity against homologous and heterologous strains elicited by two outer membrane protein serogroup B meningococcal vaccines among infants, children and adults. Eleventh international pathogenic Neisseria conference, 59. 1998. Paris, Éditions E.D.K.

Tappero JW, Lagos R, Ballesteros AM, Plikaytis BD, Williams D, Dykes J, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines. A randomised controlled trial in Chile. JAMA 1999;281:1520-27.

Thornton A, Lennon D, Rasanathan K, O´Hallahan J, Oster P, Stewart J, Tilman S, Aaberge I, Feiring B, Nøkleby H, Rosenqvist E, White K, Reid S, Mulholland K, Wakefield MJ, Martin D. Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: Beginning of epidemic control. Vaccine 2006;24:1395-1400.

Turunen H, Vuorio KA, Leinikki PO. Determination of IgG, IgM and IgA antibody responses in human toxoplasmosis by enzyme-linked immunosorbent assay (ELISA). Scand J Infect Dis 1983; 15: 307-11. 

Wedege E, Bjune G, Frøholm LO, Høiby EA, Rosenqvist E. Immunoblotting studies on vaccine and patient sera from a Norwegian serogroup B meningococcal vaccination trial. NIPH Ann 1991;14:183-86.

Wedege E, Caugant DA, Frøholm LO, Høiby EA, Rosenqvist E. Characterization of meningococcal isolates from Norwegian patients in the years 1987 to 1991. In: Conde-Glez CJ, Morse S, Rice P, Sparling F, Calderon E, eds.: Pathobiology and Immunobiology of Neisseriaceae. Instituto Nascional de Salud Publica, Cuarnavaca, 1994:318-24.

Wedege E, Høiby EA, Rosenqvist E, Bjune G. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Inf Imm 1998;66:3223-31.

Wedege E, Høiby EA. Rosenqvist E, Frøholm LO. Serotyping and subtyping of Neisseria meningitidis isolates by co-agglutination, dot-blotting and ELISA. J Med Microbiol 1990;31:195-201.

Wedege E, Nøkleby H, Bjune G. No evidence for serotype-restricted protection among teenagers vaccinated with the Norwegian group B outer membrane vesicle vaccine. J Inf Dis 1999;180:242-3.

Welch RG. Chickenpox and the Guillain-Barré syndrome. Arch Dis Child 1962;37:557-9.

Wenger JD, Perkins BA. Patterns in emergence of epidemic meningococcal disease. In: Scheld WM, Armstrong SD, Hughes JM, eds. Emerging Infectious Diseases I. Washington, DC: ASM Press; 1998:125-36.

Wong S, Lennon D, Jackson C, Stewart J, Reid S, Crengle S, Tilman S, Aaberge I, O´Hallahan J, Oster P, Mulholland K, Martin D. New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine in Children Aged 16-24 Months. Pediatr Infect Dis J 2007; 26:345-350.

Wraith DC, Goldman M, Lambert P-H. Vaccination and autoimmune disease: what is the evidence? Lancet 2003;362:1659-66.

Wyle FA, Artenstein MS, Brandt BL, Tramont EC, Kasper DL, Altieri PL, et al. Immunologic response of man to group B meningococcal polysaccharide vaccines. J Infect Dis 1972;126:514-22.

Zollinger WD, Boslego JE, Frasch CE, Frøholm LO. Safety of vaccines containing meningococcal group B polysaccharide. Lancet 1984;2:166.

Zollinger WD, Boslego J, Frøholm LO, Ray JS, Moran EE, Brandt BL. Human bactericidal antibody response to meningococcal outer membran proten vaccines. In: Poolman JT, Zanen HC, Meyer TF, Heckels JE, Makela PRH, Smith H, Beuvery EC, eds.: Gonococci and Meningococci. Kluwer Academic Publishers, Dordrecht 1988:209-17.

Zollinger WD, Boslego J, Moran E, Brandt B, Collins H, Mandrell R, et al. Bactericidal antibody response to a polyvalent meningococcal protein-polysaccharide vaccine. In: Robbins JB, Schneerson R, Klein D, Sadoff J, Hardegree MC, eds. Bacterial vaccines. Presented at Bacterial Vaccines Symposium. National Institute of Health, Bethesda Md, Sept 1984. p.245-261.

Zollinger WD, Mandrell RE, Altieri P, Berman S, Lowenthal J, Artenstein MS. Safety and immunogenicity of a Neisseria meningitidis type 2 protein vaccine in animals and humans. J Infect Dis 1978;137:728-39.

Zollinger WD, Mandrell RE, Griffiss JM, Altieri P, Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. J Clin Invest 1979:63:836-48.